Singapore markets close in 39 minutes

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.7104+0.0395 (+5.89%)
At close: 04:00PM EDT
0.7299 +0.02 (+2.74%)
After hours: 07:38PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 107.59M
Enterprise value 210.59M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.75
Price/book (mrq)63.84
Enterprise value/revenue 1.66
Enterprise value/EBITDA -2.82

Trading information

Stock price history

Beta (5Y monthly) 1.93
52-week change 3-87.59%
S&P500 52-week change 325.69%
52-week high 35.8300
52-week low 30.5400
50-day moving average 30.8548
200-day moving average 31.2640

Share statistics

Avg vol (3-month) 34.78M
Avg vol (10-day) 36.82M
Shares outstanding 5151.45M
Implied shares outstanding 6151.45M
Float 8119.55M
% held by insiders 15.67%
% held by institutions 156.72%
Shares short (15 May 2024) 422.74M
Short ratio (15 May 2024) 43.66
Short % of float (15 May 2024) 421.00%
Short % of shares outstanding (15 May 2024) 415.01%
Shares short (prior month 15 Apr 2024) 417.63M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -65.18%
Operating margin (ttm)-60.70%

Management effectiveness

Return on assets (ttm)-15.74%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)126.85M
Revenue per share (ttm)0.95
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -70.6M
Net income avi to common (ttm)-82.68M
Diluted EPS (ttm)-0.5900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)111.18M
Total cash per share (mrq)0.73
Total debt (mrq)214.18M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.68
Book value per share (mrq)-0.39

Cash flow statement

Operating cash flow (ttm)-76.01M
Levered free cash flow (ttm)-25.42M